Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s - Lubenow, N; Warkentin, TE; Greinacher, A (Thromb Res, 2006)
et al.